Cannabis use, depression and suicidal ideation in adolescence: direction of associations in a population based cohort.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 16 03 2020
revised: 18 05 2020
accepted: 22 05 2020
entrez: 16 7 2020
pubmed: 16 7 2020
medline: 16 2 2021
Statut: ppublish

Résumé

To clarify the direction of the association between frequency of cannabis use, depressive symptoms and suicidal ideation from 15 to 20 years using cross-lagged analyses. We included 1606 adolescents from the province of Québec followed since 1997 with information on frequency of cannabis use (none/monthly/weekly), depression (defined as being in the top 10% symptoms) and serious suicidal ideation at ages 15, 17 and 20 years. The prevalence of weekly cannabis use increased from 7.0% at age 15 years to 15.6% by age 20 years. Adolescents who reported using cannabis weekly at one age were 11 to 15 times more likely to continue using cannabis over time. In longitudinal cross-lagged analyses, weekly cannabis use at age 15 was associated with greater odds (OR=2.19, 95% CI=1.04-4.58) of suicidal ideation two years later. However, other substance use (alcohol, tobacco, other drugs) fully explained this association. Further, depression predicted subsequent weekly cannabis use, even after adjusting for comorbid other substance use (eg, for depression at 15 years predicting cannabis use at 17 years: OR=2.30, 95% CI=1.19-4.43). Quantity of cannabis consumed was not measured. Findings suggest that depressive symptoms in adolescence may represent a risk factor for weekly cannabis consumption, which once initiated is likely to remain chronic. Weekly cannabis use increased risk for suicidal ideation, but not independently from other substance use including alcohol, tobacco and other drugs.

Sections du résumé

BACKGROUND
To clarify the direction of the association between frequency of cannabis use, depressive symptoms and suicidal ideation from 15 to 20 years using cross-lagged analyses.
METHOD
We included 1606 adolescents from the province of Québec followed since 1997 with information on frequency of cannabis use (none/monthly/weekly), depression (defined as being in the top 10% symptoms) and serious suicidal ideation at ages 15, 17 and 20 years.
RESULTS
The prevalence of weekly cannabis use increased from 7.0% at age 15 years to 15.6% by age 20 years. Adolescents who reported using cannabis weekly at one age were 11 to 15 times more likely to continue using cannabis over time. In longitudinal cross-lagged analyses, weekly cannabis use at age 15 was associated with greater odds (OR=2.19, 95% CI=1.04-4.58) of suicidal ideation two years later. However, other substance use (alcohol, tobacco, other drugs) fully explained this association. Further, depression predicted subsequent weekly cannabis use, even after adjusting for comorbid other substance use (eg, for depression at 15 years predicting cannabis use at 17 years: OR=2.30, 95% CI=1.19-4.43).
LIMITATIONS
Quantity of cannabis consumed was not measured.
CONCLUSION
Findings suggest that depressive symptoms in adolescence may represent a risk factor for weekly cannabis consumption, which once initiated is likely to remain chronic. Weekly cannabis use increased risk for suicidal ideation, but not independently from other substance use including alcohol, tobacco and other drugs.

Identifiants

pubmed: 32663935
pii: S0165-0327(20)30934-4
doi: 10.1016/j.jad.2020.05.136
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076-1083

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There are no conflict of interest to declare.

Auteurs

Despina Bolanis (D)

McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, Montreal, Québec, Canada.

Massimiliano Orri (M)

McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, Montreal, Québec, Canada; Bordeaux Population Health Research Center, INSERM U1219, University of Bordeaux.

Natalie Castellanos-Ryan (N)

School of Psychoeducation, University of Montreal, Montreal, Québec, Canada; CHU Ste-Justine Research Centre, Montreal, Québec, Canada.

Johanne Renaud (J)

McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, Montreal, Québec, Canada; Manulife Centre for Breakthroughs in Teen Depression and Suicide Prevention, Montreal, Québec, Canada.

Tina Montreuil (T)

Department of Educational and Counselling Psychology, McGill University, Montreal, Québec, Canada;; Department of Psychiatry, McGill University, Montreal, Québec, Canada.

Michel Boivin (M)

School of Psychology, Université Laval, Québec city, Québec, Canada.

Frank Vitaro (F)

School of Psychoeducation, University of Montreal, Montreal, Québec, Canada; CHU Ste-Justine Research Centre, Montreal, Québec, Canada.

Richard E Tremblay (RE)

Department of Psychology, University of Montreal, Montreal, Québec, Canada; CHU Ste-Justine Research Centre, Montreal, Québec, Canada.

Gustavo Turecki (G)

McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, Montreal, Québec, Canada.

Sylvana M Côté (SM)

Department of Social and Preventive Medicine, University of Montreal, Québec, Canada; CHU Ste-Justine Research Centre, Montreal, Québec, Canada.

Jean R Séguin (JR)

Department of Psychiatry and Addictology, University of Montreal, Montreal, Québec, Canada; CHU Ste-Justine Research Centre, Montreal, Québec, Canada.

Marie-Claude Geoffroy (MC)

McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, Montreal, Québec, Canada; Department of Educational and Counselling Psychology, McGill University, Montreal, Québec, Canada;. Electronic address: marie-claude.geoffroy@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH